Remicade is top among biologic-naive patients with UC

Remicade ranked highest for induction of remission and endoscopic improvement among biologic-naive patients, according to a meta-analysis of treatments for moderately to severely active ulcerative colitis.In the same study, Stelara (ustekinumab, Janssen) and Xeljanz (tofacitinib, Pfizer) had the best results among patients who had been previously exposed to anti-TNF therapy.“Several treatment options are now available for the management of moderate-severe ulcerative colitis, with variable efficacy and safety profiles, and positioning different agents in treatment course, as first-lineRead More